Efficacy of empagliflozin in patients with metabolic dysfunction-associated steatotic liver disease with or without diabetes: a systematic review and meta-analysis of randomized controlled trials - Pu
2 days ago
- #SGLT2 inhibitors
- #meta-analysis
- #MASLD
- Empagliflozin, an SGLT2 inhibitor, shows potential hepatic benefits in patients with metabolic dysfunction-associated steatotic liver disease (MASLD).
- A meta-analysis of 8 RCTs involving 672 participants evaluated empagliflozin's effects on liver enzymes, steatosis, fibrosis, and metabolic outcomes.
- Empagliflozin significantly reduced ALT and AST levels compared to placebo, indicating improved liver enzyme levels.
- Triglyceride levels were also significantly reduced with empagliflozin treatment.
- No significant improvements were observed in non-invasive markers of hepatic steatosis (CAP, LSM) or fibrosis (APRI, FIB-4, NFS).
- Empagliflozin did not significantly affect body weight, BMI, fasting blood sugar, or HbA1c levels.
- The study concludes that empagliflozin improves liver enzymes and triglycerides but lacks clear benefits for steatosis or fibrosis markers.
- Further large-scale, long-term RCTs with histological endpoints are recommended to confirm empagliflozin's role in MASLD management.